Xarelto (rivaroxaban)

pCPA File Number: 21080

Negotiation Status:

Concluded with an LOI

Indication(s):

Prevention of stroke and cardiovascular events in coronary and peripheral artery disease.

Sponsor/Manufacturer:

Bayer Inc.

CDA-AMC Project Number:

SR0569-000

pCPA Engagement Letter Issued:

2019-03-29

Negotiation Process Concluded:

2019-11-15